Patients with a confirmed diagnosis of advanced gastric cancer, esophageal cancer, or colorectal cancer.
Conditions
Interventions
Sponsors
The Affliated Changzhou No. 2 People’s Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1: Aged 18-85 years, diagnosed with advanced gastric cancer, esophageal cancer, or colorectal cancer; 2: Currently receiving a platinum-based chemotherapy regimen known to easily cause thrombocytopenia; 3: Severe recurrent CTIT: In the current chemotherapy cycle, platelet count =7 days or the dose was reduced >=15% due to CTIT; 2. Previously received platelet transfusion due to CTIT; 4: ECOG performance status score 0-3, with an expected survival period >=1 month; 5: Voluntary participation and signed written informed consent form.
Exclusion criteria
Exclusion criteria: 1: Thrombocytopenia caused by non-chemotherapy factors (e.g., immune thrombocytopenia, disseminated intravascular coagulation, hypersplenism, active major bleeding, etc.); 2: Previous use of Hetrombopag + Dexamethasone; 3: Received platelet transfusion or treatment with recombinant human thrombopoietin (rhTPO) or recombinant human interleukin-11 (rhIL-11) within 72 hours prior to study drug administration; 4: Active thrombotic disease, or a clear history of arterial or venous thrombosis within the past 6 months; 5: Severe hepatic insufficiency (Child-Pugh class C); 6: Pregnant or lactating women, or those planning to conceive during the study period; 7: Presence of any serious concomitant disease or condition that, in the investigator's judgment, may increase the subject's risk or interfere with the study evaluation; 8: Women who are pregnant, breastfeeding, or planning to become pregnant during the study; 9: Patients with other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participation or whom the investigator deems unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet Treatment Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Depth of platelet recovery;Clinical bleeding events; | — |
Countries
China
Contacts
Public ContactYunqian Chu
The Affliated Changzhou No. 2 People’s Hospital of Nanjing Medical University
Outcome results
None listed